JP2023545084A5 - - Google Patents

Info

Publication number
JP2023545084A5
JP2023545084A5 JP2023521639A JP2023521639A JP2023545084A5 JP 2023545084 A5 JP2023545084 A5 JP 2023545084A5 JP 2023521639 A JP2023521639 A JP 2023521639A JP 2023521639 A JP2023521639 A JP 2023521639A JP 2023545084 A5 JP2023545084 A5 JP 2023545084A5
Authority
JP
Japan
Prior art keywords
composition
use according
antibody
allergy
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545084A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/037481 external-priority patent/WO2022075476A1/en
Publication of JP2023545084A publication Critical patent/JP2023545084A/ja
Publication of JP2023545084A5 publication Critical patent/JP2023545084A5/ja
Pending legal-status Critical Current

Links

JP2023521639A 2020-10-09 2021-10-08 Ox40関連疾患を治療するための方法 Pending JP2023545084A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063089809P 2020-10-09 2020-10-09
US63/089,809 2020-10-09
US202063116365P 2020-11-20 2020-11-20
US63/116,365 2020-11-20
US202163233592P 2021-08-16 2021-08-16
US63/233,592 2021-08-16
PCT/JP2021/037481 WO2022075476A1 (en) 2020-10-09 2021-10-08 Method for treating ox40 related disease

Publications (2)

Publication Number Publication Date
JP2023545084A JP2023545084A (ja) 2023-10-26
JP2023545084A5 true JP2023545084A5 (cg-RX-API-DMAC7.html) 2024-10-15

Family

ID=81126528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521639A Pending JP2023545084A (ja) 2020-10-09 2021-10-08 Ox40関連疾患を治療するための方法

Country Status (11)

Country Link
US (1) US20230383001A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225371A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023545084A (cg-RX-API-DMAC7.html)
KR (1) KR20230084166A (cg-RX-API-DMAC7.html)
CN (1) CN116437955A (cg-RX-API-DMAC7.html)
AU (1) AU2021358274A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198414A1 (cg-RX-API-DMAC7.html)
IL (1) IL301935A (cg-RX-API-DMAC7.html)
MX (1) MX2023004113A (cg-RX-API-DMAC7.html)
TW (1) TW202222343A (cg-RX-API-DMAC7.html)
WO (1) WO2022075476A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
IL326123A (en) * 2023-07-25 2026-03-01 Inmagene Pte Ltd Methods of treating alopecia areata and atopic dermatitis
WO2025244002A1 (ja) * 2024-05-21 2025-11-27 国立大学法人京都大学 ベンダムスチンによるt細胞の減少を抑制するために使用されるt細胞減少抑制剤
WO2025259719A1 (en) * 2024-06-10 2025-12-18 Walden Biosciences, Inc. Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease
WO2026145427A1 (en) * 2024-12-30 2026-07-09 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Bispecific antibodies targeting ox40 and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類cd134(ox40)之人類單株抗體及其製造及使用方法
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
RU2759630C2 (ru) * 2016-09-22 2021-11-16 Ридженерон Фармасьютикалз, Инк. Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
TWI787203B (zh) * 2016-09-23 2022-12-21 美商建南德克公司 Il-13拮抗劑用於治療異位性皮炎之用途
WO2019229155A1 (en) * 2018-05-31 2019-12-05 Glenmark Pharmceuticals S.A. Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders

Similar Documents

Publication Publication Date Title
JP2019515008A5 (cg-RX-API-DMAC7.html)
JP2018184417A5 (cg-RX-API-DMAC7.html)
JP2019517549A5 (cg-RX-API-DMAC7.html)
JP2019513726A5 (cg-RX-API-DMAC7.html)
JP2015525798A5 (cg-RX-API-DMAC7.html)
CN104010656B (zh) 使用免疫球蛋白和c1-抑制剂的联合疗法
JP2016530280A5 (cg-RX-API-DMAC7.html)
JP2013533858A5 (cg-RX-API-DMAC7.html)
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
JP2022512851A5 (cg-RX-API-DMAC7.html)
JP2024516698A5 (cg-RX-API-DMAC7.html)
JP2022543062A5 (cg-RX-API-DMAC7.html)
JP2024533067A5 (cg-RX-API-DMAC7.html)
JP2019521156A5 (cg-RX-API-DMAC7.html)
JP2021510523A5 (cg-RX-API-DMAC7.html)
JP2018512402A5 (cg-RX-API-DMAC7.html)
JP2022523530A5 (cg-RX-API-DMAC7.html)
JP2019519584A5 (cg-RX-API-DMAC7.html)
JP2022513029A5 (cg-RX-API-DMAC7.html)
JP2019534251A5 (cg-RX-API-DMAC7.html)
JP2023546503A5 (cg-RX-API-DMAC7.html)
JP2025500483A5 (cg-RX-API-DMAC7.html)
CN115698076A (zh) 用于治疗肿瘤的药物
JP2023500480A5 (cg-RX-API-DMAC7.html)
JP2023531090A5 (cg-RX-API-DMAC7.html)